Enhanced Krev-1 expression inhibits the growth of pancreatic adenocarcinoma cells
Related Experiment Video
Updated: Oct 29, 2026
Growing Desmoplastic Three-Dimensional Pancreatic Cancer Spheroids from Co-Culture
Published on: September 27, 2024
S D Leach1, D H Berger, B S Davidson
1Department of Surgery, University of Texas-M.D. Anderson Cancer Center, Houston, USA.
Abstract:
Pancreatic ductal adenocarcinoma is characterized by a high rate of activating mutations involving codon 12 of the K-ras protooncogene. As a means of ras-targeted intervention, the effects of enhanced Krev-1 gene expression on the growth and tumorigenicity of the hamster pancreatic adenocarcinoma cell line PC-1 were evaluated. Overexpression of the Krev-1 gene product resulted in morphologic reversion to a less transformed phenotype, as well as retarded growth kinetics and diminished potential for anchorage-independent growth. Among six transfected cell lines, the magnitude of these changes correlated with the degree of Krev-1 overexpression as assessed by Western blot. When PC-1 cells overexpressing high levels of the Krev-1 gene product were assessed for tumorigenicity in syngeneic animals, an increased latency to tumor growth and a decreased tumor size were noted. The results confirm that overexpression of the Krev-1 gene may provide a useful strategy for ras-targeted intervention in this disease.
Insights
Enhanced Krev-1 gene expression suppressed pancreatic cancer growth and tumorigenicity. This ras-targeted intervention strategy shows promise for treating pancreatic ductal adenocarcinoma by reverting cancer cells to a less malignant state.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Genetics
Background:
- Pancreatic ductal adenocarcinoma frequently harbors activating mutations in the K-ras protooncogene at codon 12.
- Ras signaling pathways are critical in cancer development and progression.
Purpose of the Study:
- To investigate the therapeutic potential of Krev-1 gene overexpression as a ras-targeted intervention strategy.
- To evaluate the impact of enhanced Krev-1 expression on the growth and tumorigenicity of pancreatic cancer cells.
Main Methods:
- Transfection of hamster pancreatic adenocarcinoma cell line PC-1 with the Krev-1 gene.
- Assessment of morphologic changes, growth kinetics, and anchorage-independent growth.
- Correlation of phenotypic changes with Krev-1 overexpression levels via Western blot.
- Evaluation of tumorigenicity in syngeneic animal models.
Main Results:
- Krev-1 gene overexpression led to morphologic reversion towards a less transformed phenotype.
- Enhanced Krev-1 expression resulted in retarded cell growth and reduced anchorage-independent growth.
- Tumorigenicity studies showed increased latency and decreased tumor size in animals with Krev-1 overexpressing cells.
- The magnitude of phenotypic changes correlated with the level of Krev-1 overexpression.
Conclusions:
- Overexpression of the Krev-1 gene effectively inhibits pancreatic cancer cell growth and tumorigenicity.
- Krev-1 gene therapy represents a viable strategy for ras-targeted intervention in pancreatic ductal adenocarcinoma.
- Modulating Krev-1 expression offers a potential therapeutic avenue for pancreatic cancer treatment.
